Financial Performance - For the three months ended September 30, 2025, ONCONETIX, INC. reported revenue of $303,651, a decrease of 25.4% compared to $406,859 for the same period in 2024[16] - The gross profit for the three months ended September 30, 2025, was $268,894, significantly higher than the gross profit of $105,414 in the same period of 2024[16] - The net loss for the three months ended September 30, 2025, was $8,783,702, compared to a net loss of $3,827,405 for the same period in 2024, reflecting an increase in losses[16] - For the nine months ended September 30, 2025, the net loss was $19.7 million, a decrease from a net loss of $29.3 million for the same period in 2024, representing a 32.5% improvement[24] - The company reported a net cash used in operating activities of $6.6 million for the nine months ended September 30, 2025, compared to $9.6 million for the same period in 2024, indicating a 31.5% reduction in cash outflow[24] Assets and Liabilities - Total current assets increased to $1,302,026 as of September 30, 2025, from $950,267 as of December 31, 2024, representing a growth of 37%[14] - Total liabilities decreased to $16,303,023 as of September 30, 2025, from $18,571,008 as of December 31, 2024, indicating a reduction of approximately 12.2%[14] - The total stockholders' equity decreased to $3,374,121 as of September 30, 2025, from $8,542,627 as of December 31, 2024, reflecting a decline of 60.5%[14] - The accumulated deficit increased to $136,884,245 as of September 30, 2025, from $115,683,621 as of December 31, 2024, showing a rise of 18.3%[14] Stock and Equity Transactions - The weighted average number of common shares outstanding for the three months ended September 30, 2025, was 1,405,469, compared to 15,366 for the same period in 2024[16] - The company issued 765,029 shares in connection with the exercise of preferred investment options[19] - The Company raised approximately $12.9 million from the Series D PIPE Financing, resulting in net cash proceeds of $9.3 million[157] - The Series D Preferred Stock was classified as permanent equity and recorded at par value, while the Series D Warrants were classified as liability-classified instruments[160] Impairments and Losses - The company incurred a loss on impairment of goodwill amounting to $11.5 million for the nine months ended September 30, 2025, compared to $15.5 million in the prior year[24] - The Company recorded an intangible asset impairment charge of approximately $3.5 million during the nine months ended September 30, 2024, due to competitive pressures[71] - The Company recognized a loss on extinguishment of $5,384,719 related to the debt extinguishment transaction during the three and nine months ended September 30, 2025[159] Revenue Sources - The company generated 100% of its other revenue from the European Union during the three months ended September 30, 2025[59] - For the nine months ended September 30, 2025, product sales accounted for 93% of total revenue, with the remaining 7% from the European Union[59] - Customer A accounted for 100% of development services revenue for the three months ended September 30, 2025[61] Financing and Debt - The Company entered into an ELOC Purchase Agreement allowing for the sale of up to $25 million in common stock, with 30% of gross proceeds allocated to redeem Series C Preferred Stock[169] - The Company issued a non-convertible debenture of $5.0 million to a related party with an interest rate of 4.0% per annum[115] - The Company recognized approximately $0.3 million and $0.8 million of interest expense for the three and nine months ended September 30, 2025, respectively[111] Future Outlook and Concerns - Management plans to generate product revenue from Proclarix sales, which is still subject to further development and commercialization[40] - The company continues to face substantial doubt about its ability to continue as a going concern within one year from the issuance of the financial statements[41]

As filed with the Securities and Exchange Commission on November 4, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Onconetix, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 83-2262816 (I.R.S. Employer Identification No.) 201 E. Fifth Street, Suite ...

As filed with the Securities and Exchange Commission on October 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Onconetix, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 83-2262816 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 201 E. Fifth Street, Suite ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41294 Onconetix, Inc. (Exact name of registrant as specified in its charter) | Delaware | 83-2262816 | | --- | --- | | (State or ...

Financial Performance - Total revenue for Q1 2025 was $101,630, a decrease of 85.5% compared to $700,433 in Q1 2024[17] - Gross profit for Q1 2025 was $45,832, down 75.7% from $189,000 in Q1 2024[17] - Net loss for Q1 2025 was $8,545,885, compared to a net loss of $11,118,572 in Q1 2024, representing a 23.1% improvement[17] - Operating expenses for Q1 2025 totaled $12,616,661, an increase from $11,270,990 in Q1 2024[17] - The company reported a basic and diluted net loss per share of $0.53 for Q1 2025, compared to $20.08 for Q1 2024[17] - Revenue for the three months ended March 31, 2025, was approximately $0.1 million, a decrease from $0.7 million for the same period in 2024[54] - Product sales accounted for 93% of total revenue in the three months ended March 31, 2025, while development services accounted for 100% of revenue[54] Assets and Liabilities - Total current assets increased to $2,420,589 as of March 31, 2025, from $950,267 as of December 31, 2024, a growth of 154.5%[15] - Total liabilities decreased to $14,258,469 as of March 31, 2025, down 23.5% from $18,571,008 as of December 31, 2024[15] - Goodwill decreased significantly to $16,209,509 as of March 31, 2025, from $27,048,973 as of December 31, 2024, a reduction of 40.2%[15] - Cash and cash equivalents increased to $1,577,193 as of March 31, 2025, from $646,500 as of December 31, 2024, a rise of 144.5%[15] - Total stockholders' equity decreased to $3,992,793 as of March 31, 2025, from $8,542,627 as of December 31, 2024, a decline of 53.3%[15] - As of March 31, 2025, Onconetix had cash of approximately $1.6 million and a working capital deficit of approximately $11.6 million, with an accumulated deficit of approximately $125.4 million[35] Impairment and Expenses - The company incurred a loss on impairment of goodwill amounting to $10,918,000 for the three months ended March 31, 2025, compared to $5,192,000 in the prior year, indicating a 110% increase in impairment losses[23] - The company recognized goodwill impairment losses of approximately $10.9 million for the three months ended March 31, 2025, compared to $5.2 million for the same period in 2024[65] - The company recorded full impairments of intangible assets acquired from the acquisitions of Proteomedix and ENTADFI, resulting in a zero balance as of March 31, 2025[60] - The company incurred net periodic benefit costs of $16,134 for the three months ended March 31, 2025, compared to a net periodic benefit cost of $(6,733) for the same period in 2024[169] Capital Structure and Financing - The company redeemed Series C preferred stock amounting to approximately $1.71 million in 2025, indicating ongoing efforts to manage its capital structure[35] - The company has two non-interest-bearing notes payable of $5.0 million each, with maturity dates of April 19, 2024, and September 30, 2024[75] - A non-convertible debenture of $5.0 million was issued to a related party with an interest rate of 4.0% per annum, originally payable by June 30, 2024[91] - The maturity date of the related party debenture was extended to October 31, 2024, with no other terms modified[92] - The Company issued a promissory note to Keystone Capital Partners, LLC with an aggregate principal amount of $117,647.06, due by November 12, 2025[100] - The Company raised $2,000,000 from the sale of 3,499 Series C Preferred Stock and warrants to purchase 591,856 shares of common stock on October 2, 2024[121] - The Company received approximately $4.8 million under the Equity Line of Credit (ELOC) during the three months ended March 31, 2025[125] Business Operations and Strategy - Onconetix acquired Proteomedix AG on December 15, 2023, enhancing its capabilities in prostate cancer diagnosis with the Proclarix diagnostic product[26] - The company has abandoned the commercialization of ENTADFI due to insufficient resources and is exploring options for the sale of ENTADFI assets[28] - Management plans to generate product revenue from Proclarix and seeks additional funding through equity or debt financing to support ongoing operations[36] - The company is focusing on the commercialization of Proclarix, an in vitro diagnostic test for prostate cancer, which is expected to generate revenue by 2027[185][192] - The company has no products approved for sale aside from Proclarix and has not generated any revenue from product sales to date[193] Corporate Governance and Management - The company is currently searching for a permanent Chief Executive Officer and Chief Financial Officer[187] - The Company has entered into a potential business combination with Ocuvex Therapeutics, Inc., which would result in Ocuvex equity holders owning approximately 90% of the Company post-transaction[177] Tax and Regulatory Matters - The Company recorded an income tax benefit of approximately $127,000 for the three months ended March 31, 2024, yielding an effective tax rate of 21.3% for Proteomedix[161] - The Company has recorded a full valuation allowance against its U.S. deferred tax assets due to uncertainty around utilizing these tax attributes[162]

Financial Performance - As of December 31, 2024, the company reported a working capital deficit of approximately $17.3 million and an accumulated deficit of approximately $113.0 million[28]. - The company has incurred net losses since inception and expects to continue doing so, with significant fluctuations in losses anticipated based on various operational activities[28]. - The company generated negative operating cash flows of $10.5 million for the year ended December 31, 2024[198]. - The company incurred a net loss of $58.7 million and $37.4 million for the years ended December 31, 2024 and 2023, respectively, with an accumulated deficit of $115.7 million as of December 31, 2024[198]. - The company has no assurance of generating sufficient revenue to support self-sustaining cash flows, raising substantial doubt about its ability to continue as a going concern[30]. - The company has abandoned the commercialization of ENTADFI due to cash constraints and is seeking to sell or transact the ENTADFI assets[205]. - The company plans to seek funding through a combination of equity offerings, debt financing, or other capital sources, which may not be available on favorable terms[207]. Product Development and Commercialization - Proclarix is an in vitro diagnostic test for prostate cancer, approved for sale in the European Union, and is expected to be marketed in the U.S. as a lab-developed test[23]. - Proclarix aims to address the issue of overdiagnosis in prostate cancer, which can lead to unnecessary biopsies and increased healthcare costs[48]. - Proclarix generated revenues of $86,957 in 2024, while prior to its acquisition by Onconetix, Proteomedix had revenues of $67,380 from Proclarix sales[49]. - The marketing approval process for Proclarix is lengthy and unpredictable, and the company cannot commercialize Proclarix in the U.S. without obtaining approval from CMS and state agencies[210]. - The company’s ability to commercialize its product depends on obtaining adequate reimbursement from government health programs and private insurers[219]. - Coverage and reimbursement for newly approved products may be delayed and may not cover the costs of manufacture, sale, and distribution[220]. Regulatory Compliance - The company received multiple deficiency notices from Nasdaq regarding compliance with listing standards, including failure to maintain a minimum bid price and timely filing of reports[38][40][41]. - The EMA requires a risk management plan (RMP) for all new MAAs, detailing measures to minimize risks associated with the product[153]. - Compliance with the General Data Protection Regulation (GDPR) is mandatory for processing personal health data in the EU, imposing significant obligations on pharmaceutical companies[137]. - Regulatory approval processes vary significantly between countries, impacting the timeline and requirements for marketing products internationally[139]. - The IVDR introduces significant changes for IVD manufacturers, including a new risk-based classification system and stricter regulatory responsibilities throughout the supply chain[159]. Partnerships and Acquisitions - The company signed a Non-Binding Letter of Intent with Ocuvex Therapeutics for a potential business combination, where Ocuvex equity holders would own approximately 90% of the combined company[33]. - Proteomedix entered an exclusive partnership with LabCorp in 2023 for the commercialization of Proclarix in the United States, receiving an upfront license fee and future royalty payments[109]. - The company entered into an asset purchase agreement to acquire six FDA-approved pharmaceutical assets for a total of $8.5 million in cash and 1 million shares of common stock[74][75]. - The partnership with Immunovia AB aims to leverage Proteomedix's R&D capabilities to accelerate the roll-out of their proprietary IMMray PanCan-d test[179]. - Proteomedix has entered into a research and development partnership with New Horizon Health Limited to enhance cancer patient management[178]. Market Opportunity and Competitive Landscape - In 2022, there were 1,467,854 new cases of prostate cancer and 397,430 related deaths worldwide, highlighting the significant market opportunity for Proclarix[114]. - The worldwide market for in vitro diagnostic (IVD) products is projected to be valued at $101 billion in 2024, with Europe and North America being the largest markets[116]. - The molecular diagnostics field is highly competitive, with many companies developing tests for prostate cancer, but Proclarix offers advantages such as being blood-based and minimally invasive[120]. - Proclarix is positioned as a complementary tool to MRI-based diagnosis, supporting the decision-making process for patients undergoing MRI and targeted biopsy[127]. Product Features and Efficacy - Proclarix is designed to indicate the risk of clinically significant prostate cancer using a risk score derived from a clinical decision support system[86]. - Proclarix has demonstrated a 90% sensitivity and a 95% negative predictive value for clinically significant prostate cancer in clinical studies[95]. - The validation study showed that Proclarix could reduce unnecessary biopsies by approximately 43% compared to clinical comparators[95]. - EAU guidelines recommend using Proclarix as an additional biomarker test to reduce negative biopsies in men with PSA levels between 3–10 ng/mL[99]. - Proclarix was included in the 2023 AUA/SUO clinical practice guideline, emphasizing its role in the early detection of clinically significant prostate cancer (GG2+) and improving biopsy safety[100]. Financial Instruments and Debt - The Company issued a non-convertible debenture to the PMX Investor for $5 million, with an interest rate of 4% per annum[62]. - The Altos Debenture was amended to extend the maturity date to October 31, 2024, and the outstanding debt was settled through the issuance of units[64]. - Following the PMX Transaction, sellers owned approximately 87.2% of Onconetix's outstanding equity interests[55]. - The PMX Transaction involved Onconetix issuing shares valued at approximately $75 million as consideration for the acquisition of Proteomedix[52]. - The fair value of the shares issued in the PMX Transaction was approximately $65.1 million, based on the closing price of $9.528 per share[53].

Revenue and Profitability - Revenue for the three months ended September 30, 2024, was $406,859, compared to $0 for the same period in 2023, representing a significant increase[22]. - Gross profit for the nine months ended September 30, 2024, was $395,130, with total operating expenses of $27,738,007, leading to a loss from operations of $27,342,877[22]. - The net loss for the three months ended September 30, 2024, was $3,827,405, compared to a net loss of $5,346,908 for the same period in 2023[22]. - The net loss for the nine months ended September 30, 2024, was $5,346,908, compared to a net loss of $14,306,704 for the same period in the previous year[24]. - For the nine months ended September 30, 2024, the company reported a net loss of $29,252,681 compared to a net loss of $15,058,822 for the same period in 2023[28]. Assets and Liabilities - Total current assets decreased to $1,047,939 as of September 30, 2024, from $5,838,271 as of December 31, 2023[19]. - Total liabilities decreased slightly to $20,896,798 as of September 30, 2024, from $21,877,471 as of December 31, 2023[19]. - The company reported an accumulated deficit of $86,038,875 as of September 30, 2024, compared to $56,786,194 as of December 31, 2023[19]. - The total stockholders' equity increased to $41,022,620 as of September 30, 2024, from $1,404,476 as of December 31, 2023[19]. - As of September 30, 2024, the company had cash of approximately $341,495, down from $7,653,975 at the end of the previous period[28]. - The company has a working capital deficit of approximately $16.3 million and an accumulated deficit of approximately $86.0 million as of September 30, 2024[41]. Stock and Equity - The weighted average number of common shares outstanding for the three months ended September 30, 2024, was 1,306,146, compared to 438,039 for the same period in 2023[22]. - The company had a total of 8,326,281 common stock shares outstanding as of September 30, 2024[24]. - Stock-based compensation for the nine months ended September 30, 2024, amounted to $272,781[24]. - The total additional paid-in capital as of September 30, 2024, was $119,563,869[24]. - The Company issued 2,696,729 shares of Series B Convertible Preferred Stock, convertible into approximately 6,741,820 shares of common stock upon Stockholder Approval obtained on September 5, 2024[192]. - The Company has authorized the issuance of up to 250,000,000 shares of common stock and 10,000,000 shares of preferred stock as of September 30, 2024[185]. Impairments and Adjustments - The company incurred a total of $15,453,000 in goodwill impairment and $3,530,716 in impairment of ENTADFI assets during the current reporting period[28]. - The company recorded approximately $1.5 million in acquisition-related costs during 2023, which were expensed[142]. - The Company recorded an impairment charge of approximately $14.7 million on the ENTADFI asset group during the fourth quarter of 2023, along with a $1.2 million impairment on acquired inventory[109]. - The company recognized a cumulative impairment charge of $15.5 million related to goodwill for the nine months ended September 30, 2024, with a balance of $38.9 million as of September 30, 2024[90][92]. Acquisitions and Strategic Moves - On December 15, 2023, the company acquired 100% of Proteomedix AG, enhancing its capabilities in prostate cancer diagnosis[32]. - The company has paused the commercialization of ENTADFI and is exploring strategic alternatives, including a potential sale of the ENTADFI assets[34]. - The Company acquired ENTADFI for a total possible consideration of $100 million, with initial consideration of $20 million paid upon closing and additional payments scheduled for 2024[96][97]. - The Company entered into an asset purchase agreement with WraSer for $3.5 million in cash at signing and $4.5 million in cash at closing, along with 25,000 shares of common stock and a $500,000 payment one year post-closing[113]. Financing and Cash Flow - The company entered into an Equity Financing Line of Credit (ELOC) on October 2, 2024, to address its cash flow needs[41]. - The company recorded a net cash used in investing activities of $24,597 for the current period, significantly lower than $9,864,613 in the previous period[28]. - Management plans to secure additional funding through equity or debt financings, but current ELOC funds are insufficient to sustain operations[42]. - The Company executed three non-interest-bearing notes payable totaling $14.0 million, with maturity dates ranging from September 30, 2023, to September 30, 2024[152]. Future Outlook and Risks - The company has significant uncertainty regarding its ability to sustain operations due to historical and expected operating losses, with no commitments for further financing[43]. - The company may need to curtail future clinical trials and product development if additional capital is not secured[42]. - The Company is in the process of finalizing the initial accounting for the business combination, with a deadline of December 15, 2024, for completing the measurement period[129]. Miscellaneous - The company operates in one segment: commercial, with performance evaluated by the chief operating decision maker[47]. - The company has no new accounting pronouncements that could significantly affect its financial statements, except for upcoming disclosures required by FASB[69]. - The Company recorded a change in fair value of the related party subscription agreement liability of approximately $928,000 for the three months ended September 30, 2024[183].

Financial Performance - Revenue for the three months ended June 30, 2024, was $704,848, compared to $1,405,281 for the same period in 2023, representing a decrease of approximately 50%[7] - Gross profit for the six months ended June 30, 2024, was $289,716, down from $1,115,565 in the previous year, indicating a significant decline[7] - Net loss for the three months ended June 30, 2024, was $(14,306,704), compared to a net loss of $(6,865,270) for the same period in 2023, which is an increase in loss of approximately 108%[7] - The company reported a total comprehensive loss of $(14,230,110) for the three months ended June 30, 2024, compared to $(6,865,270) for the same period in 2023, reflecting an increase in comprehensive loss of approximately 107%[7] - For the six months ended June 30, 2024, Onconetix reported a net loss of $25,425,276, compared to a net loss of $9,711,914 for the same period in 2023, indicating a significant increase in losses[10] - The net loss for the three months ended June 30, 2024, was approximately $14.3 million, compared to a net loss of $6.9 million in the same period in 2023, reflecting an increase of 108.4%[98] - The company reported a net loss of $14.3 million and $25.4 million for the three and six months ended June 30, 2024, respectively, with an accumulated deficit of $82.2 million[128] Assets and Liabilities - Current assets decreased from $5,838,271 to $2,035,448, a decline of approximately 65.2%[5] - Total assets decreased from $87,518,032 to $59,463,955, a decrease of approximately 32.0%[5] - Stockholders' equity decreased from $5,295,114 to $3,169,727, a decline of about 40.2%[6] - The balance of accumulated deficit as of June 30, 2024, was $(82,211,470), compared to $(56,786,194) at December 31, 2023, indicating an increase in deficit of approximately 45%[9] - As of June 30, 2024, the company had cash of approximately $930,541, down from $9,222,647 at the end of June 2023, highlighting a cash decrease of approximately 90% year-over-year[10] - The working capital deficit stood at approximately $18.6 million as of June 30, 2024, with an accumulated deficit of approximately $82.2 million[13] - As of June 30, 2024, the company had total current liabilities of approximately $20.6 million, including accounts payable of approximately $3.2 million and notes payable primarily due to Veru[133] Impairments and Expenses - Impairment of goodwill for the six months ended June 30, 2024, was $15,453,000, compared to $10,261,000 for the same period in 2023, showing an increase of approximately 51%[7] - The Company recorded an impairment loss of approximately $10.3 million related to goodwill and approximately $1.2 million on assets acquired from the ENTADFI acquisition during the three months ended June 30, 2024[102] - Total operating expenses for the three months ended June 30, 2024, were $13,715,735, compared to $6,649,600 in the same period of 2023, reflecting an increase of approximately 106%[7] - Total operating expenses for the six months ended June 30, 2024, increased by approximately $15.5 million compared to $9.5 million in the same period in 2023, marking a 163.1% increase[105] Strategic Focus and Risks - The company is focused on commercializing Proclarix and integrating assets from Proteomedix AG[4] - Future financial performance is subject to various risks, including the need for substantial additional capital[4] - The company is reliant on third parties for manufacturing and distribution, which poses potential risks[4] - Market acceptance of products and competition from existing therapies are critical for future growth[4] - The company has paused commercialization of ENTADFI and is exploring strategic alternatives, including a potential sale of the ENTADFI assets, due to cash constraints[11] - The company is considering strategic options for ENTADFI, including a potential sale or abandonment, as there is currently no plan to commercialize the product[134] Funding and Capital Needs - The company anticipates requiring significant additional capital in the short-term to fund ongoing operations and satisfy existing obligations[115] - Management's plans for funding include generating product revenue from Proclarix sales, which are still subject to successful commercialization[113] - The company plans to secure additional funding through equity or debt financings, but currently has no commitments in place for further financing[130] - If stockholder approval is not obtained by January 1, 2025, the Series B Convertible Redeemable Preferred Stock could be redeemable for approximately $41.9 million[113] Compliance and Regulatory Issues - The company reported stockholders' equity of $1,404,476 for the fiscal year ended December 31, 2023, which is below the Nasdaq minimum requirement of $2,500,000[137] - The company has until September 16, 2024, to regain compliance with the Nasdaq Bid Price Rule after receiving a notice of non-compliance due to a closing bid price below $1.00 per share[137] - The company has until November 4, 2024, to regain compliance with the Minimum Stockholders' Equity Requirement after submitting a compliance plan to Nasdaq[137] Operational Challenges - The company has incurred net losses since inception and expects to continue incurring losses, with significant fluctuations based on research and development activities[89] - There is substantial doubt about the company's ability to continue as a going concern within one year from the issuance of the financial statements[113] - The company has developed a remediation plan to address material weaknesses in internal controls, including the termination of the accounting employee involved in credit card misuse[125]

As filed with the Securities and Exchange Commission on June 24, 2024 Registration No. 333-277066 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Onconetix, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 83-2262816 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 201 E ...

As filed with the Securities and Exchange Commission on June 4, 2024 Registration No. 333-277066 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Onconetix, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 83-2262816 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) with c ...